Disruption of the EMILIN-1/integrin pathway influences microenvironmental changes in gastric cancer development
By
Alessandra Capuano
Maddalena Vescovo
Samanta Muzzin
Enrica Timis
Laura Cesaratto
Eliana Pivetta
Roberto Doliana
Antonio Palumbo
Renato Cannizzaro
Vincenzo Canzonieri
Eugenio Scanziani
Simone Canesi
Gustavo Baldassarre
Maurizio Mongiat
Paola Spessotto
July 20, 2026
Disruption of the EMILIN-1/integrin pathway influences microenvironmental changes in gastric cancer development
Overview This study investigates the role of EMILIN-1 in the tumor microenvironment of gastric cancer (GC), revealing that GC cells utilize a dual escape strategy to evade EMILIN-1 mediated surveillance.
Background Gastric cancer is a leading cause of cancer-related mortality, often diagnosed at advanced stages. The tumor microenvironment plays a crucial role in tumor progression, influencing cell behavior and immune responses.
Data Highlights No numerical data or trial data provided in the source material.
Key Findings EMILIN-1 is identified as a tumor-suppressive component in the gastric mucosa. GC cells exhibit epigenetic silencing of ITGA4, preventing α4β1 integrin expression. Loss of EMILIN-1 production in stromal fibroblasts and lymphatic endothelial cells is observed. GC cells adopt a dual escape strategy to evade EMILIN-1 mediated stromal surveillance. Alterations in the tumor microenvironment are noted in gastric cancer. Clinical Implications The findings highlight the EMILIN-1/integrin pathway in gastric cancer development.
Conclusion The study elucidates mechanisms by which gastric cancer cells disrupt the EMILIN-1/integrin pathway.
Related Resources & Content
Gastric Cancer — The Role of EMILIN-1 in Modulating the Tumor Microenvironment and Inhibiting Gastric Cancer Development and Progression, 2024 -- Title Gastric Cancer — Integrin β1 regulates abnormal cell-matrix interactions and invasive characteristics in cells with dysfunctional E-cadherin, 2021 -- Title Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy, 2026 -- Title GLIS3 drives epithelial–mesenchymal transition and cancer stem–like traits in stomach adenocarcinoma via TGFBR3–Hedgehog signaling, 2026 -- Title Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update, 2025 -- Title Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study, 2025 -- Title Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study | Journal of Clinical Oncology Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update - PubMed
